LiveSpo COLON provides a specific liquid-vial record: three named Bacillus species, a combined spore count and water as the stated vehicle. That makes the preparation identifiable even though its marketing is substantially more treatment-oriented than many digestive supplements.
The official English-language manufacturer page includes claims about colitis, clinical results and an FDA-related document. Those statements require careful boundaries. This review reports the current international record without treating it as a verified US medicine, a cure or personal permission to use the product. Its inclusion is an evidence comparison, not an endorsement of every claim on the page.
Keep this distinction in view
The page declares three billion CFU per five-milliliter vial but no strain codes. Its colitis, FDA-document and universal-suitability statements remain unverified seller claims.
The current record identifies a five-milliliter vial
The manufacturer page names LiveSpo COLON and declares three billion CFU of spores in a five-milliliter vial with reverse-osmosis water. The quantity describes the stated product unit rather than a personal intake or course of treatment.
The page is an international English-language company record with Vietnam research references. This review does not transfer its claims into verified US transaction availability or a current US regulatory determination. The formula-match guide explains why product, market and preparation need to remain attached to an evidence claim.
Three species are named without reference codes
The declaration names B. subtilis, B. clausii and B. coagulans. It does not return individual strain codes or an allocation of the combined count among those entries. A familiar Bacillus species in another supplement cannot fill those missing identities.
NIH ODS explains why specific strains matter in clinical interpretation. The organism guide follows that distinction. The MegaSporeBiotic review and Just Thrive review provide different spore records, not evidence that their codes, methods or results belong to this vial.
The viable count remains a combined declaration
Three billion CFU is the manufacturer’s total per vial. The reviewed text does not establish an explicit guaranteed numerical count at expiration, a method for testing it or a full current package panel. This article does not divide the total equally among the species or infer a shelf-life promise.
The quantity chapter keeps those details separate from volume and organism count. A liquid format also does not create a swallowing workaround or personal compatibility conclusion. No vial-handling, mixing, medicine-spacing or individual use instructions are supplied in this review.
The treatment language is attributed rather than endorsed
The page calls the product supportive treatment for ulcerative colitis and makes additional statements about colitis symptoms and healing. Those are strong manufacturer claims. The reviewed product record does not supply the full controlled report and independent regulatory evidence needed to verify them as universal treatment conclusions.
The article does not diagnose colitis or recommend replacing conventional care. NCCIH cautions against using probiotics to postpone attention to a health problem. A seller’s mechanism explanation cannot identify the cause of a reader’s complaint, establish a clinical cure or supply a substitute for individual medical assessment.
The reported Vietnam trial has an incomplete method record
The manufacturer describes a randomized, blinded, controlled Vietnam hospital study and states particular symptom and colon findings. That is a company summary of a study, not a complete trial report reviewed here. The precise participant group, comparator and analytical methods are not established from the summary.
The study-method guide keeps that distinction visible. The page also mentions customer-care survey results concerning children; those should not be merged with the hospital trial. This review does not infer a GLP-1-treatment cohort or transfer a reported colitis result into a prescription-side-effect outcome.
An FDA-document claim does not establish drug approval here
The page says a document was approved under NDI 1167. The reviewed material does not provide the underlying FDA decision document or establish what it concluded. This article therefore does not repeat that wording as verified approval of a drug to treat colitis.
FDA’s supplement explanation distinguishes dietary-supplement marketing from general premarket safety-and-effectiveness approval. That is framework context, not a product-specific legal verdict. The manufacturer’s broad suitability statements likewise do not establish individual eligibility, and no live US stock, legal sales conclusion or dispensing arrangement is inferred from the public page.
The identifiable formula does not validate the broader promise
LiveSpo supplies named species, a combined vial quantity and a stated vehicle. Those are useful composition facts. Its major open questions concern strain references, current label, viable-count timepoint and the full methods and regulatory records behind its strong treatment language.
This review has not purchased the product, tested a lot or obtained clinical signoff. It offers no regimen or personal safety clearance. The international product record remains distinct from a verified medicine and from a proven GLP-1 replacement. Comparing its claims accurately requires keeping their source and uncertainty visible, rather than treating every company statement as an established medical outcome.
Sources for this article
LiveSpo COLON - Livespo
Current official product declaration and attributed claims; no independent assay or personal clinical clearance
Checked 2026-10-01
https://livespo.com/livespos-product/livespo-colon/Office of Dietary Supplements - Probiotics
Federal evidence and safety context; bounded sections only, not product endorsement
Checked 2026-10-01
https://ods.od.nih.gov/factsheets/Probiotics-HealthProfessional/Probiotics: Usefulness and Safety
Federal evidence and safety context; bounded sections only, not product endorsement
Checked 2026-10-01
https://www.nccih.nih.gov/health/probiotics-usefulness-and-safetyFDA: Information for Consumers Using Dietary Supplements
Current federal consumer framework, exact same-day cached origin; no product approval or individual advice
Checked 2026-10-01
https://www.fda.gov/food/dietary-supplements/information-consumers-using-dietary-supplements